Summary: A large genetic study of more than 2.2 million people reshapes our understanding of addiction. The research shows that most genetic risk for substance use disorders (SUDs) comes not from how the body metabolizes a drug, but from genes that shape brain systems for reward processing, impulse control and behavioral disinhibition.
By analyzing genetic data related to alcohol, tobacco, cannabis and opioid use together, researchers identified a dominant “externalizing” pathway—a set of genetic influences tied to reward sensitivity and poor impulse regulation—that underlies much of the vulnerability to addiction across substances.
Key Facts & Statistics
- Scope: The study pooled genome-wide data from over 2.2 million individuals, making it one of the largest analyses to separate shared from substance-specific genetic effects.
- Two major pathways identified:
- Broad externalizing pathway: Genes that affect reward processing, self-control and risk-taking. These variants overlap with genetic signals for ADHD, conduct problems and other impulsive behaviors.
- Substance-specific pathways: Narrow genetic effects related to particular drugs—for example, genes involved in alcohol metabolism or nicotinic receptors that influence tobacco use.
- Brain-focused risk: Senior author Danielle Dick emphasizes that addiction risk is primarily about brain wiring—how individuals evaluate consequences and control impulses—rather than purely biological responses to substances.
- Neural mechanisms: Many genes associated with the broad liability are involved in neural signaling and plasticity, highlighting the importance of how the brain adapts to rewards.
- Polygenic prediction: The team created polygenic scores that predict general vulnerability to addiction across substances, while substance-specific scores can give more precise risk estimates for particular drugs.
Source: Rutgers University
Overview
A Rutgers Health–led team, led by Holly Poore of Rutgers Robert Wood Johnson Medical School, combined results from multiple published genome-wide association studies to investigate genetic influences on alcohol, tobacco, cannabis and opioid use disorders. Their multivariate approach examined these SUDs alongside related externalizing traits—such as ADHD, risk-taking and initiation of substance use—to better distinguish shared from drug-specific genetic effects.
The analysis revealed that most genetic liability for SUDs operates through a common, broad externalizing pathway linked to behavioral disinhibition. This shared genetic architecture accounts for overlaps among addiction, ADHD and other impulsive, risk-taking behaviors. Layered on top of this shared liability are narrower, substance-specific genetic influences—for example, genes that alter alcohol metabolism or the sensitivity of nicotine receptors.
Danielle Dick, director of the Rutgers Addiction Research Center, explains that these findings shift the focus from body-centered explanations to brain-centered mechanisms: genes that shape how people process rewards and regulate behavior are central to addiction risk. The study provides genomic evidence separating these broad versus specific pathways for the first time at this scale.
Using advanced genomic tools, the team identified hundreds of genetic variants associated with the broad externalizing liability and additional variants specific to particular substances. Joint modeling of SUDs with externalizing traits increased discovery power while preserving the ability to detect substance-specific signals. Many broad-liability genes map to neural signaling and plasticity pathways, whereas substance-specific genes map to biological systems directly related to particular drugs.
Translational implications
The researchers built polygenic scores—aggregate measures combining thousands of genetic variants—that were particularly effective at predicting general vulnerability across multiple substance use disorders. Substance-specific scores helped identify risk for particular substances such as nicotine or alcohol. As Dick notes, genetic risk scores are not destiny; they provide a “vulnerability map” that can target prevention, early intervention and tailored treatment strategies. For example, individuals with high genetic disinhibition might benefit from programs that strengthen self-regulation, while substance-specific risk profiles could guide monitoring and focused support.
The study also performed network and drug-target analyses to highlight biological systems and potential therapeutic targets. These results point to opportunities for repurposing medications or developing treatments that enhance inhibitory control and normalize reward signaling, addressing broad risk across multiple addictive behaviors rather than a single substance.
Limitations include the predominance of participants of European ancestry, reflecting current large-scale genetic datasets. The authors note the urgent need for more diverse genomic research to ensure findings apply equitably across populations.
Key Questions Answered:
A: No. Shared genetic architecture means ADHD and addiction share some vulnerability factors related to impulse control, but genes indicate risk, not inevitability. Early identification of elevated genetic disinhibition could allow targeted prevention to strengthen self-regulation and reduce the likelihood of substance use initiation.
A: Broad genetic factors create a foundation of vulnerability (impulsivity, poor inhibition), while substance-specific genes and environmental exposures influence which substance a person is most likely to misuse. Both layers contribute to individual outcomes.
A: Yes. Identifying genes and pathways involved in broad disinhibition suggests therapeutic strategies aimed at enhancing cognitive control or modifying reward processing. Such approaches could have benefits across multiple substance use disorders.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this genetics and addiction research news
Author: Patti Zielinski
Source: Rutgers University
Contact: Patti Zielinski – Rutgers University
Image: The image is credited to Neuroscience News
Original Research: Multivariate genetic analyses of 2.2 million individuals reveal broad and substance-specific pathways of addiction risk by Holly E. Poore et al., published in Nature Mental Health. DOI: 10.1038/s44220-026-00608-6. Open access.
Abstract
Multivariate genetic analyses of 2.2 million individuals reveal broad and substance-specific pathways of addiction risk
Many gene-mapping efforts study one substance use disorder at a time even though SUDs commonly co-occur and share genetic roots with other externalizing behaviors. This study used multivariate genomic analyses and biological annotation to examine whether including related externalizing traits boosts discovery without losing specificity. Joint analysis of SUDs with other externalizing traits increased insights into neurobiological pathways for both broad and substance-specific risk. The findings support a model where genetic risk for SUDs largely operates through pathways shared with behaviors characterized by behavioral disinhibition, with additional substance-specific genetic contributions.